Table 3. Estimated vaccination coverage with selected vaccines and doses among adolescents 13–17 years, by year and sampling frame, 

National Immunization Survey-Teen, 2016-2017

2016 2017

Vaccine Single Dual Difference* Single Dual Difference*

% (95% CI) % (95% CI) Percentage Points 

(95% CI)

% (95% CI) % (95% CI) Percentage Points 

(95% CI)

HPV vaccine – all adolescents

 UTD † 43.7 

(42.3 , 45.1)

43.4

(42.1 , 44.7)

0.3

(-0.3 , 0.7)

49.6

(48.1 , 51.1)

48.6 

(47.3 , 49.9)

1.0

(0.4 , 1.4) §

 ≥1 dose 60.8 

(59.4 , 62.2)

60.4 

(59.2 , 61.6)

0.4

(-0.1, 0.9)

66.4 

(65.1 , 67.7)

65.5 

(64.3 , 66.7)

0.9

(0.4, 1.4) §

HPV vaccine – females

 UTD 50.0 

(47.9 , 52.1)

49.5 

(47.6 , 51.4)

0.5 

(-0.4 , 1.0)

53.4 

(51.3 , 55.5)

53.1 

(51.2 , 55.0)

0.3 

(-0.6 , 1.0)

 ≥1 dose 65.7 

(63.8 , 67.6)

65.1 

(63.4 , 66.8)

0.6

(0.0, 1.2)

68.9 

(67.0 , 70.8)

68.6 

(66.9 , 70.3)

0.3

(-0.4, 1.0)

HPV vaccine – males

 UTD 37.7 

(35.8 , 39.6)

37.5 

(35.8 , 39.2)

0.2 

(-0.5 , 0.9)

46.0 

(43.9 , 48.1)

44.3 

(42.6 , 46.0)

1.7 

(1.0 , 2.4)

 ≥1 dose 56.1 

(54.1 , 58.1)

56.0 

(54.3 , 57.7)

0.1

(-0.6, 0.8)

64.0 

(62.1 , 65.9)

62.6 

(61.0 , 64.2)

1.4

(0.7, 2.1) §

MenACWY

 ≥1 dose 82.0 

(80.8 , 83.2)

82.2 

(81.2 , 83.2)

-0.2

(-0.5, 0.1)

85.3 

(84.2 , 86.4)

85.1 

(84.2 , 86.0)

0.2

(-0.2, 0.6)

 ≥2 doses 40.3 

(37.0 , 43.6)

39.1 

(36.1 , 42.1)

1.2

(0.0, 2.4)

44.2 

(40.6 , 47.8)

44.3 

(41.4 , 47.2)

-0.1

(-1.2, 1.0)
2016 2017

Vaccine Single Dual Difference* Single Dual Difference*

% (95% CI) % (95% CI) Percentage Points 

(95% CI)

% (95% CI) % (95% CI) Percentage Points 

(95% CI)

Tdap 

 ≥1 dose 88.0 

(86.9 , 89.1)

88.0 

(87.1 , 88.9)

0.0

(-0.4, 0.4)

88.7 

(87.7 , 89.7)

88.7 

(87.8 , 89.6)

0.0

(-0.3, 0.3)

MMR 

 ≥2 doses 91.0 

(90.2 , 91.8)

90.9 

(90.2 , 91.6)

0.1

(-0.2, 0.4)

92.0 

(91.2 , 92.8)

92.1 

(91.4 , 92.8)

-0.1

(-0.3, 0.1)

Hepatitis B vaccine 

 ≥3 doses 91.6 

(90.8 , 92.4)

91.4 

(90.7 , 92.1)

0.2

(-0.1, 0.5)

91.9 

(91.1 , 92.7)

91.9 

(91.2 , 92.6)

0.0

(-0.2, 0.2)

Varicella vaccine

 History of varicella disease 15.2 

(14.2 , 16.2)

15.2 

(14.3 , 16.1)

0.0

(-0.3, 0.3)

13.1 

(12.1 , 14.1)

13.2 

(12.3 , 14.1)

-0.1

(-0.4, 0.2)

 No history of varicella disease

 ≥1 vaccine dose 95.0 

(94.2 , 95.8)

95.0 

(94.3 , 95.7)

0.0

(-0.2, 0.2)

95.6 

(94.9 , 96.3)

95.5 

(94.8 , 96.2)

0.1

(-0.1, 0.3)

 ≥2 vaccine dose 85.4 

(84.2 , 86.6)

85.6 

(84.6 , 86.6)

-0.2

(-0.6, 0.2)

88.5 

(87.4 , 89.6)

88.6 

(87.7 , 89.5)

-0.1

(-0.4, 0.2)

 History of varicella disease or 

receipt of ≥2 varicella vaccine doses

87.6 

(86.6 , 88.6)

87.8 

(86.9 , 88.7)

-0.2

(-0.5, 0.1)

90.0 

(89.1 , 90.9)

90.1 

(89.3 , 90.9)

-0.1

(-0.4, 0.2)

Abbreviations: HPV = human papillomavirus; MenACWY = quadrivalent meningococcal conjugate vaccine; Tdap = tetanus, diphtheria, and pertussis 

vaccine; MMR = measles, mumps, and rubella vaccine. 

Note: “Single”=cell-phone, “Dual”=landline & cell-phone, CI=confidence interval

*Difference=Single%-dual%

† HPV UTD includes those with ≥ 3 doses, and those with 2 doses when the first HPV vaccine dose was initiated prior to age 15 years and there was 

at least five months minus four days between the first and second dose. This update to the HPV recommendation occurred in December of 2016.

§ Denotes statistically significant difference between single- and dual-frame estimates